Skip to main content
. 2020 Oct 20;2020:7801093. doi: 10.1155/2020/7801093

Table 3.

Complication rates reported for OVDs.

Author (year) OVDs N (eyes) Adverse events (rates in %)
Auffarth (2017) Twinvisc 109 Ocular hypertension (12.6%), corneal edema (0.9%), cystoid macular edema (0.9%); IOP ≥ 30 mmHg in 6 hours postop (6.5%), 24 hours (0.9%), 7 days (0.9%), 30 days (0%), 90 days (0%)

DuoVisc 111 Ocular hypertension (17.6%), corneal edema (0.9%), inflammation (0.9%), capsule break (0.9%), bubbles in Viscoat OVD (0.9%); IOP ≥ 30 mmHg in 6 hours postop (7.2%), 24 hours (0%), 7 days (0%), 30 days (0%), 90 days (0%)

Espindola (2012) DisCoVisc 39 No intraoperative and postoperative complications
2% HPMC 39

Hutz (1996) Methocel 50 Pressure peaks up to 44 mm·Hg requiring acetazolamide (Diamox) treatment occurred twice in the Healon GV group and once in the Healon group postoperatively. Peaks up to 38 mm·Hg occurred three times in the Viscoat group, and peaks up to 35 mm Hg occurred six times in the Methocel group
Viscoat 50
Healon 50
Healon GV 50

Oshika (2004) Healon5 78 IOP elevation (5.1%), corneal edema (2.5%), nausea and vomiting (1.3%)
Healon 79 IOP elevation (1.3%), corneal edema (1.3%)

Oshika (2010) DisCoVisc 154 IOP ≥ 30 mmHg in 5 h postop (7.2%)
Healon5 163 IOP ≥ 30 mmHg in 5 h postop (7.4%), mild corneal edema (0.6%), macular edema (0.6%)

Ray-Chaudhary (2006) Ophthalin 51 No significant difference in the number of complications between the two groups
HPMC-Ophtal 52

Rainer (2007) NaHa 1% 40 IOP ≥ 30 mmHg in 30 mins postop (3%), 1 hour postop (5%), 2 hours postop (3%), 3 hours postop (5%), 4 hours postop (8%), 6 hours postop (13%), 8 hours postop (8%), 20–24 hours postop (0%)
2% HPMC 40 IOP ≥ 30 mmHg in 30 mins postop (8%), 1 hour postop (13%), 2 hours postop (23%), 3 hours postop (13%), 4 hours postop (8%), 6 hours postop (10%), 8 hours postop (10%), 20–24 hours postop (0%)

Thirumalai (2007) Healon GV 415 In 2 hours follow-up: IOP ≥ 30 mmHg (7.2%), IOP ≥35 mmHg (4%). In 24-hour follow-up: IOP ≥ 30 mmHg (8.8%), IOP ≥ 35 mmHg (4%). In 2-day follow-up: IOP ≥30 mmHg (7%), IOP ≥ 35 mmHg (3.5%)